Pyxis Oncology (PYXS)
(Delayed Data from NSDQ)
$4.15 USD
-0.02 (-0.48%)
Updated May 17, 2024 04:00 PM ET
After-Market: $4.17 +0.02 (0.48%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PYXS 4.15 -0.02(-0.48%)
Will PYXS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PYXS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PYXS
Pyxis Oncology, Inc. (PYXS) Reports Q1 Loss, Tops Revenue Estimates
Does Pyxis Oncology (PYXS) Have the Potential to Rally 61.29% as Wall Street Analysts Expect?
PYXS: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Pyxis Oncology (PYXS) Rating Upgrade to Buy
Down -15.56% in 4 Weeks, Here's Why You Should You Buy the Dip in Pyxis Oncology, Inc. (PYXS)
Pyxis Oncology, Inc. (PYXS) Upgraded to Strong Buy: What Does It Mean for the Stock?
Other News for PYXS
Wall Street Analysts Are Bullish on Top Healthcare Picks
Buy Rating Affirmed for Pyxis Oncology on Strong Financials and Promising Clinical Progress
Buy Rating Affirmed for Pyxis Oncology on Robust Clinical Pipeline and Solid Financials
Pyxis Oncology GAAP EPS of -$0.06, revenue of $16.1M
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024